Cryptococcal meningitis
diseaseOn this page
Also known as Cryptococcus neoformans caused infectious meningitisCryptococcus neoformans infectious meningitis
Summary
Cryptococcal meningitis (MONDO:0005723) is a disease and 33 clinical trials. Top therapeutic interventions include amphotericin b, fluconazole, and flucytosine. A subtype of cryptococcosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Cryptococcal meningitis |
| Mondo ID | MONDO:0005723 |
| EFO | EFO:0007228 |
| MeSH | D016919 |
| DOID | DOID:0080159 |
| NCIT | C174113 |
| SNOMED CT | 14232007 |
| UMLS | C0085436 |
| MedGen | 88410 |
| GARD | 0024223 |
| Is cancer (heuristic) | no |
Also known as: Cryptococcus neoformans caused infectious meningitis · Cryptococcus neoformans infectious meningitis
Disease family
This is a subtype of cryptococcosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › cryptococcosis › Cryptococcal meningitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Amphotericin B | Approved (phase 4) |
| Fluconazole | Approved (phase 4) |
| Sertraline | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dexamethasone, Efungumab, Flucytosine, INTERFERON GAMMA-1B, Itraconazole.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 13 |
| PHASE4 | 5 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06178627 | PHASE4 | ENROLLING_BY_INVITATION | Amphotericin B for Non-HIV Cryptococcal Meningitis Patients |
| NCT00976040 | PHASE4 | COMPLETED | Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis |
| NCT01075152 | PHASE4 | COMPLETED | Cryptococcal Optimal ART Timing Trial |
| NCT01535469 | PHASE4 | COMPLETED | Operational Research for Cryptococcal Antigen Screening |
| NCT02686853 | PHASE4 | UNKNOWN | Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis |
| NCT03945448 | PHASE2/PHASE3 | RECRUITING | Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia |
| NCT06666322 | PHASE2/PHASE3 | RECRUITING | Platform Trial For Cryptococcal Meningitis |
| NCT01589289 | PHASE3 | COMPLETED | Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC |
| NCT01715922 | PHASE2/PHASE3 | UNKNOWN | Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa |
| NCT01802385 | PHASE3 | COMPLETED | Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis |
| NCT04140461 | PHASE3 | UNKNOWN | AmB Dose for Cryptococcal Meningitis |
| NCT05541107 | PHASE3 | UNKNOWN | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 |
| NCT00145249 | PHASE2 | COMPLETED | Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis |
| NCT00324025 | PHASE2 | TERMINATED | Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS |
| NCT00847678 | PHASE2 | TERMINATED | Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS |
| NCT00885703 | PHASE1/PHASE2 | COMPLETED | High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals |
| NCT04031833 | PHASE1/PHASE2 | COMPLETED | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) |
| NCT06414512 | PHASE2 | COMPLETED | Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis |
| NCT02955862 | PHASE1 | COMPLETED | Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report |
| NCT04072640 | EARLY_PHASE1 | UNKNOWN | Three Induction Treatments on Cryptococcal Meningitis |
| NCT00001352 | Not specified | RECRUITING | Fungal Infection Susceptibility |
| NCT00867269 | Not specified | RECRUITING | Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia |
| NCT00830856 | Not specified | COMPLETED | Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa |
| NCT02098525 | Not specified | COMPLETED | Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy |
| NCT02136030 | Not specified | UNKNOWN | Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis |
| NCT02434172 | Not specified | COMPLETED | CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa |
| NCT02624453 | Not specified | UNKNOWN | Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS |
| NCT03226379 | Not specified | COMPLETED | Driving Reduced AIDS-associated Meningo-encephalitis Mortality |
| NCT03267407 | Not specified | UNKNOWN | Vietnam Cryptococcal Retention in Care Study - Version 2.1 |
| NCT04296292 | Not specified | COMPLETED | The Lived Experience of Participants in an African Randomised Trial |
| NCT04532463 | Not specified | COMPLETED | Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis |
| NCT05471063 | Not specified | UNKNOWN | Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis |
| NCT05685641 | Not specified | UNKNOWN | Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AMPHOTERICIN B | 4 | 10 |
| FLUCONAZOLE | 4 | 5 |
| FLUCYTOSINE | 4 | 4 |
| EFAVIRENZ | 4 | 1 |
| VORICONAZOLE | 4 | 1 |
| EFUNGUMAB | 3 | 2 |
| CHEMBL207216 | 0 | 1 |
| CHEMBL6067678 | 0 | 1 |
| CHEMBL4785395 | 0 | 1 |
Related Atlas pages
- Drugs: Amphotericin B, Fluconazole, Flucytosine, Efavirenz, Voriconazole, Efungumab